Core Viewpoint - Achieve Life Sciences is advancing its cytisinicline program for nicotine dependence treatment, announcing a partnership with Adare Pharma Solutions for manufacturing, and is on track for a potential U.S. commercial launch in the first half of 2027 [1][3][4]. Company Developments - Achieve has made significant progress towards regulatory approval, with the FDA accepting the New Drug Application (NDA) for cytisinicline, targeting a PDUFA date of June 20, 2026 [4][8]. - The company completed the ORCA-OL long-term exposure trial with 334 participants, providing extensive safety data that exceeds FDA requirements [4]. - Cytisinicline has been selected for the FDA Commissioner's National Priority Voucher for e-cigarette cessation, which will facilitate expedited review [4][10]. Partnership and Manufacturing - The partnership with Adare Pharma Solutions aims to reduce risks associated with international pharmaceutical importation and lower costs, including potential tariffs [2][3]. - Achieve has begun technology transfer to Adare, enhancing supply chain redundancy and U.S.-based contingency capacity [3][4]. Financial Performance - As of December 31, 2025, Achieve reported cash, cash equivalents, and marketable securities totaling $36.4 million [6]. - Total operating expenses for Q4 2025 were $14.7 million, with a net loss of $14.7 million for the quarter and $54.7 million for the full year [6][17]. Clinical and Scientific Advancements - Achieve's clinical program demonstrates cytisinicline's potential to address nicotine dependence, with findings indicating efficacy regardless of prior treatment history [5][11]. - Recent data published in JAMA Internal Medicine reaffirm cytisinicline's efficacy and tolerability for smoking cessation [4][5].

Core Viewpoint - Achieve Life Sciences, Inc. is conducting a public offering of 15 million shares of common stock and accompanying warrants at a price of $3.00 per share, aiming to raise approximately $45 million to support the development of cytisinicline for nicotine dependence treatment [1][4]. Company Overview - Achieve Life Sciences is a late-stage specialty pharmaceutical company focused on developing and commercializing cytisinicline as a treatment for nicotine dependence and smoking cessation [7]. - The company submitted a New Drug Application to the FDA for cytisinicline in June 2025, based on successful Phase 3 studies and an open-label safety study [7]. Offering Details - The public offering includes 15 million shares and warrants, with an additional 2.25 million shares available for underwriters to purchase [1][3]. - Each common warrant can be exercised for common stock at $3.00 or for pre-funded warrants at $2.999, expiring five years from issuance [2]. Financial Aspects - The gross proceeds from the offering are expected to be around $45 million, which will be used for advancing cytisinicline towards FDA approval and for general corporate purposes [4]. - The offering is expected to close around June 30, 2025, pending customary closing conditions [3]. Market Context - There are approximately 29 million adult smokers in the U.S., with tobacco use being the leading cause of preventable death [8]. - Cytisinicline has been granted Breakthrough Therapy designation by the FDA to address the need for effective treatments for nicotine e-cigarette cessation, as there are currently no FDA-approved options for this indication [9].